WASHINGTON — Congress has rebuffed drug companies’ appeals to reduce how much they have to pay for some seniors’ prescription costs — a rare defeat for the industry after a frenzied lobbying campaign.

Drug makers had pressed Republicans to use a sprawling appropriations deal to roll back a policy that makes them responsible for 70 percent of the prescription costs for seniors who reach the so-called “donut hole” in 2019. The “donut hole” is a gap in Medicare drug coverage in which beneficiaries are on the hook for sky-high prescription costs, up to a certain dollar amount.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What a novel idea, increasing the rebates so that seniors won’t go broke before they break out of the donut hole. This is no surprise. Some makers of five and six figure drugs have already warned in their Forward Guidances that rebates will be increasing in 2018, with losses falling to their bottom line as they shed crocodile tears.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy